Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effects of angiotensin-converting enzyme inhibitor and steroid therapy on proteinuria in FSGS: a retrospective study in a single clinic
Autore:
Stiles, KP; Abbott, KC; Welch, PG; Yuan, CM;
Indirizzi:
Walter Reed Army Med Ctr, Dept Med, Serv Nephrol, Washington, DC 20307 USAWalter Reed Army Med Ctr Washington DC USA 20307 Washington, DC 20307 USA DDEAMC, Dept Med, Serv Nephrol, Washington, DC USA DDEAMC Washington DC USA AMC, Dept Med, Serv Nephrol, Washington, DC USA
Titolo Testata:
CLINICAL NEPHROLOGY
fascicolo: 2, volume: 56, anno: 2001,
pagine: 89 - 95
SICI:
0301-0430(200108)56:2<89:EOAEIA>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
FOCAL-SEGMENTAL GLOMERULOSCLEROSIS; GLOMERULAR SCLEROSIS; DIABETIC NEPHROPATHY; NEPHROTIC SYNDROME; ADULTS; PROGNOSIS; ENALAPRIL;
Keywords:
FSGS; corticosteroids; angiotensin-converting enzyme inhibitors nephrotic syndrome; HMG-CoA reductase inhibitors;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
24
Recensione:
Indirizzi per estratti:
Indirizzo: Yuan, CM Walter Reed Army Med Ctr, Dept Med, Serv Nephrol, 6900 Georgia Ave NW, Washington, DC 20307 USA Walter Reed Army Med Ctr 6900 Georgia Ave NWWashington DC USA 20307
Citazione:
K.P. Stiles et al., "Effects of angiotensin-converting enzyme inhibitor and steroid therapy on proteinuria in FSGS: a retrospective study in a single clinic", CLIN NEPHR, 56(2), 2001, pp. 89-95

Abstract

We retrospectively evaluated the response to steroids (S) +/- angiotensin-converting enzyme inhibitors (ACEI) vs. ACEI in nephrotic patients with FSGS seen in our clinic from 1992 - 1999. Of 48 patients with biopsy-proven FSGS, 30 had pretherapy and follow-up evaluations of proteinuria. Of these, 22 were nephrotic (greater than or equal to 3 g protein/24 h). Twelve/22 were treated with S and 10/22 with ACEI +/- HMG-CoA reductase inhibitor (statin) alone. 92% of S patients received ACEI during follow-up, 83% concurrently with steroid treatment. The two cohorts (S vs. ACEI) were not different in age (34 +/- 12 vs. 33 +/- 12), sex (75% vs. 78% male), or ethnicity (83% vs. 83% African American). Mean follow-up time was 16 (range 4 - 61 months)vs. 23 months (range 6 - 56 months). Mean S dose was 70 mg qd (range 60 - 100 mg), with mean treatment duration of 4 months. Nephrotic patients were compared with regard to degree of proteinuria at follow-up. There were no complete remissions (proteinuria less than or equal to 200 mg/24 h) in either group. There was no difference in partial remissions (> 200 mg to < 3 g proteinuria/24 h) between the two groups - 5/12 vs. 6/10 (p = 0.434). There was no difference in the proportion of patients progressing to ESRD. Although proteinuria decreased significantly with time in both groups, there was no significant treatment effect. There was no significant time or treatmenteffect on serum creatinine. Mean arterial pressure and serum cholesterol were not significantly different between the groups. Thus, treatment with S /- ACEI is no more effective in reducing proteinuria in FSGS than treatment with ACEI alone.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 22:22:22